Sinopharm's COVID-19 vaccine was less effective in offering protection against the disease among the elderly, according to the results of a Hungarian study.
The study of 450 participants who had received two doses of the vaccine showed measurable antibody levels were present in about 90% of people under the age of 50, but the protection reduced as age increased.
The estimated probability of no antibody response was about 25% in people aged 60 and about 50% at the age of 80 years, according to the study, which was published on medRxiv https://bit.ly/3BvNgIl earlier this week and has not been peer-reviewed.
Several elderly subjects were unable to produce any protective antibodies, suggesting that measures should be put in place to prevent